The U.S. Food and Drug Administration granted priority review status to Eisai Co. Ltd.'s antiepileptic drug Fycompa.
The Japanese drugmaker filed a supplemental new drug application to expand the use of Fycompa, also known as perampanel, to include treating children ages 2 to 12 with partial onset seizures or primary generalized tonic-clonic seizures.
Partial onset seizures start in only one side of a patient's brain and are more subtle and harder to spot. Tonic-clonic seizures, also known as grand mal seizures, affect the entire brain and may cause loss of consciousness and convulsions.
Last year, Fycompa was approved by the U.S. FDA as a single treatment to treat certain seizures in patients aged 12 and older with epilepsy.
